J&J reports positive Phase 3 Tremfya data in ulcerative colitis

Key Takeaways

• QUASAR maintenance: Week 44 clinical remission 50.0% (200 mg q4w) and 45.2% (100 mg q8w) versus 18.9% placebo.
• Among remitters, about 67–71% also reached endoscopic remission (Mayo endoscopic subscore 0) at Week 44 in reported analyses.
• FDA approved TREMFYA for adult UC on September 11, 2024, based on the Phase 2b/3 QUASAR program.
• Patient Assistance and reimbursement strategy remain separate from efficacy claims and should be tracked as access variables.

What did Phase 3 QUASAR show?

Johnson & Johnson presented Phase 3 QUASAR maintenance results showing both subcutaneous TREMFYA regimens beat placebo on clinical remission at Week 44. The randomized withdrawal design enrolled adults who had responded to 12 weeks of intravenous TREMFYA induction, then assigned them to 200 mg every four weeks, 100 mg every eight weeks, or placebo withdrawal.

Major secondary endpoints included corticosteroid-free clinical remission, maintenance of clinical remission, clinical response, symptomatic remission, endoscopic improvement, and related mucosal outcomes. Company disclosures are summarized in the September 11, 2024 PR Newswire FDA-approval release.

How does the FDA UC approval change the story?

The FDA approved TREMFYA for adults with moderately to severely active ulcerative colitis on September 11, 2024. J&J positioned guselkumab as a fully human IL-23p19 antibody that also binds CD64 on IL-23–producing cells. Prior labels already covered plaque psoriasis and active psoriatic arthritis; UC added a third major immunology franchise indication.

Peer-reviewed maintenance detail is available via PMC11345979, which reports the Week 44 remission rates and notes no new safety signals in the maintenance analysis.

Why Johnson and Johnson TREMFYA Patient Assistance matters now

Positive Phase 3 data and an FDA UC label do not automatically translate into paid claims. Specialty biologics in IBD face step edits, prior authorization, and coinsurance. Johnson and Johnson TREMFYA Patient Assistance and related support channels can influence real-world starts for eligible patients, but they are commercial access tools—not clinical endpoints. Access teams should separate QUASAR efficacy from program eligibility criteria when modeling net price and abandonment risk.

Trial design and competing IBD context

QUASAR (NCT04033445) is a multicenter Phase 2b/3 program with dose-ranging induction, confirmatory Phase 3 induction, and Phase 3 maintenance. Eligible adults had moderately to severely active UC and inadequate response or intolerance to conventional therapy, prior biologics, and/or JAK inhibitors.

• Induction path: IV TREMFYA leading into SC maintenance for responders
• Maintenance primary endpoint: clinical remission at Week 44
• Registry reference: ClinicalTrials.gov NCT04033445

What investors should watch next

Follow-on Crohn’s disease data, subcutaneous induction options, head-to-head IBD studies, and payer coverage updates will determine whether UC approval expands share against other IL-23 and anti-integrin agents. Remission durability beyond Week 44 and real-world persistence under Patient Assistance versus commercial insurance are the practical commercial questions.

What remains unproven

QUASAR does not prove superiority to every marketed UC biologic in a head-to-head design. Long-term safety beyond the reported maintenance window, pediatric UC use, and net pricing after rebates remain outside the Phase 3 efficacy claims. Patient Assistance enrollment volumes are not disclosed in the FDA-approval wire and should not be invented.

Related NovaPharma coverage

• Sanofi completes Inhibrx acquisition for $1.7B
• AbbVie closes $8.7B Cerevel deal
• Amgen MariTide Phase 2 obesity data

Frequently Asked Questions

Primary Sources

1. J&J TREMFYA UC FDA approval — PR Newswire
2. PMC: QUASAR Phase 3 maintenance results
3. ClinicalTrials.gov NCT04033445 — QUASAR